What is EVOTEC?
EVOTEC operates as a global platform company dedicated to the discovery and development of highly effective therapeutics. Leveraging a data-driven, multimodality platform, the company engages in both proprietary and partnered research. Its core mission is to accelerate the availability of innovative treatments to patients worldwide, employing a unique combination of cutting-edge technologies to develop first-in-class and best-in-class pharmaceutical products. The company's strategic approach to drug development positions it as a key player in the biopharmaceutical innovation landscape.
How much funding has EVOTEC raised?
EVOTEC has raised a total of $772.9M across 8 funding rounds:
Stock Offering
$69.4M
Share Placement
$32.5M
Share Placement
$96.1M
Debt
$89.8M
Grant
$23.8M
Private Equity
$292.4M
Grant
$8.5M
Debt
$160.4M
Stock Issuance/Offering (1999): $69.4M, investors not publicly disclosed
Share Placement (2013): $32.5M led by Biotechnology Value Fund
Share Placement (2017): $96.1M supported by Novo A/S
Debt (2017): $89.8M featuring European Investment Bank
Grant (2019): $23.8M backed by Bill & Melinda Gates Foundation
Private Equity (2020): $292.4M with participation from Novo Holdings and Mubadala
Grant (2022): $8.5M led by German Federal Ministry of Education and Research
Debt (2023): $160.4M supported by European Investment Bank
Key Investors in EVOTEC
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on investments within the healthcare sector.
Mubadala
Mubadala is a global investment company based in Abu Dhabi, United Arab Emirates, with a mandate to create sustainable financial returns across diversified sectors.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is dedicated to supporting individuals experiencing hunger and extreme poverty and improving global health outcomes.
What's next for EVOTEC?
The recent major enterprise-level funding signifies a pivotal stage for EVOTEC, likely enabling the acceleration of its drug development pipeline and the expansion of its research capabilities. This strategic capital infusion is expected to fuel further innovation, potentially leading to new therapeutic breakthroughs and expanded global reach. The company's established track record of securing diverse forms of financing, from equity and debt to grants, suggests a robust financial strategy aimed at sustainable long-term growth and the successful translation of research into patient-ready treatments.
See full EVOTEC company page
